Circio Holding ASA
10.64
NOK
-0.60
(-5.34%)
ISIN
NO0013033795
Return %
Stock
S&P 500
1Y
1,731.41
14.20
3Y
3.75
81.12
5Y
- -
68.34
Capital Structure
NOK
•
in mil. unless spec.Working Capital
NOK
•
in mil. unless spec.Growth Rates
NOK
•
in mil. unless spec.Semi-annual Revenue
NOK
•
in mil. unless spec.Semi-annual Earnings Per Share
NOK
•
in mil. unless spec.Semi-annual Dividends Per Share
NOK
•
in mil. unless spec.Company Description
- CEO
- Erik Digman Wiklund
- Full Time Employees
- 9
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Tordenskiolds gate 2 Oslo AK Norway 0160
- IPO Date
- Jun 16, 2014
- Website
- targovax.com
- Similar Companies
- Business
- Circio Holding ASA, a clinical stage biotechnology company, develops circular RNA–based gene therapies and immunotherapy medicines with the aim of enabling durable, targeted RNA solutions for cancer and genetic disorders. The company operates primarily through its wholly owned subsidiary Circio AB in Sweden, leveraging its circVec platform to produce intracellular circular RNA with enhanced stability and protein expression, supporting both viral and non-viral delivery modalities. Circio maintains a portfolio that includes cancer vaccine programs and immune-activating approaches, alongside legacy immuno-oncology assets such as TG01, evaluated in externally sponsored clinical studies. Circio’s strategic focus centers on advancing its circRNA-based therapeutics from preclinical development toward early clinical milestones, with ongoing collaborations and partnerships to de-risk and accelerate its pipeline. Founded in 2016, Circio is headquartered in Stockholm, Sweden, and maintains operations in Europe, pursuing collaborations with academic and industry partners to validate its circRNA platform across oncology and rare disease contexts. The company positions itself as a platform mover in RNA therapeutics, emphasizing durable protein expression, scalable manufacturing concepts, and versatility across delivery systems to broaden its potential therapeutic reach. Circio’s governance and investor relations activities are coordinated from its Oslo listing on the Oslo Stock Exchange, reflecting a European focus and a strategy to attract partnerships and funding to fund its R&D and pipeline advancement over the near term.